The Economic Cost of Undertreated Adult ADHD

In "The Economic Cost of Undertreated Adult ADHD," the panel confronts a barrier to treatment that has nothing to do with pharmacology: cost, coverage, and medication shortages.

The panel turns to medication accessibility, agreeing that even an excellent medication is worthless if a patient cannot obtain it. Panelists note that recent shortages, while genuinely distressing for patients doing well on an unavailable medication, have created unexpected openings to finally try an alternative that had previously been deferred simply because the patient was managing well enough. Branded medications avoid shortages but often face pharmacy and insurance approval delays instead. On cost, the panel challenges the common assumption that generic automatically means affordable, citing a patient who paid $350 for four months of generic extended-release methylphenidate because of a high deductible. Predictable pricing, the panel argues, helps patients budget for treatment more comfortably than fluctuating generic costs.

Providers are encouraged to know which pharmacies reliably process manufacturer vouchers and prior authorizations, and to tell patients to call the office rather than accept an inflated price at the counter. The panel credits independent, lower-turnover pharmacies with going the extra mile compared with high-turnover chain staff who need frequent retraining on coupon programs. Panelists cite research on the broader economic cost of inadequately treated ADHD, spanning added medical visits, behavioral health care, lost productivity, DUIs, and substance abuse treatment. One striking data point: despite a higher sticker price, patients on a longer-acting liquid extended-release amphetamine product spent roughly $8,000 less per year overall on ADHD-related costs than patients on cheaper alternatives.

The panel shares a case of a recent graduate who nearly lost his new job after his usual medication was unavailable for twelve days from a large chain pharmacy, receiving two workplace warnings before he agreed to try a new medication.

"Matching ADHD Medication to the Individual Patient" returns to the exam room to explain how providers can match a specific medication to a specific patient's daily reality.